Jennifer has more than 20 years’ experience in corporate communications, investor relations, public relations, and finance. Throughout her consulting career, Jennifer has worked with a broad array of private and public life science, technology, and financial services companies, helping clients think strategically about communications as an opportunity to achieve their business goals and execute on those strategies. On the corporate side, Jennifer has served as head of communications at Cubist Pharmaceuticals, Cadus Pharmaceutical, and Tetraphase Pharmaceuticals, where she was responsible for all investor- and media-related strategy development and implementation, as well as internal and external corporate communications and community affairs. Her previous positions also include, Vice President at SmallCaps Online Group (now SCO Capital Management), where she provided comprehensive communications and financial advisory services to private and public life science and technology companies, and Assistant Vice President at Merrill Lynch as a sellside analyst following the mid-cap and specialty pharmaceutical sector. She has also held positions as a consultant and research scientist at various academic institutions, biotechnology, and pharmaceutical companies.
Jennifer holds a BA in Biochemistry from the University of Pennsylvania and an MBA from Columbia Business School, where she made Dean's List and was selected for membership in the Beta Gamma Sigma honor society. Jennifer was a 20-year member of the National Investor Relations Institute (NIRI), previously serving on the Board of Directors of the Boston Chapter, and a former co-chair of the Communications Committee at MassBIO. Jennifer completed the first level of the CFA exam and was previously Series 7 certified.
With more than 20 years of corporate communications, investor relations and PR experience on the corporate and agency sides, Susan is a seasoned professional focusing on the biotechnology and pharmaceutical sectors, as well as medical devices and specialty pharma. Most recently, she served as a consultant with BCC Partners, providing strategic planning and execution of branding, competitive positioning, communications and investor relations services to public and private companies in the life sciences industry. Prior, she was Director of Corporate Communications & Investor Relations at Alteon where she was responsible for helping the management team reposition the company, expanding Alteon’s visibility and serving as the liaison for the analyst community, institutional investors and shareholders. Susan also held a similar position at The Liposome Company, a pioneer in the development of liposomal compounds for cancer and other indications. Previously, as a consultant, she was responsible for publicizing Genentech’s GUSTO clinical trial results of Activase t-PA and helped launch Lederle’s Pro-Step nicotine patch. Susan also served as Senior Account Executive at Cohn & Wolfe where her clients included several large pharma companies and Coca-Cola USA. She also has a background in non-profit public relations, most recently as a consultant to the Biotechology Industry Organization (BIO) and the Epilepsy Foundation, and also serving as Associate Director of Magazine Relations for the American Cancer Society (ACS) and as a member of the coalition comprised of the ACS, the American Heart Association and the American Lung Association.
Susan graduated magna cum laude from Ithaca College, New York, with a BA teaching degree in English and a minor in Communications/Applied Writing.